Smart drugs: Tyrosine kinase inhibitors in cancer therapy

被引：394

作者：

Shawver, LK

Slamon, D

Ullrich, A

机构：

[1] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany

[2] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA

[3] SUGEN Inc, San Francisco, CA 94080 USA

来源：

CANCER CELL | 2002年 / 1卷 / 02期

关键词：

D O I：

10.1016/S1535-6108(02)00039-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development.

引用

页码：117 / 123

页数：7

共 61 条

[1] Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 [J].